Please login to the form below

Not currently logged in
Email:
Password:

medicines access

This page shows the latest medicines access news and features for those working in and with pharma, biotech and healthcare.

EMA to review Bluebird’s blood disorder gene therapy

EMA to review Bluebird’s blood disorder gene therapy

Bluebird Bio announced late last week that the European Medicines Agency has accepted its gene therapy LentiGlobin for accelerated review. ... LentiGlobin is already part of the EMA’s Adaptive Pathways pilot programme, which aims to improve timely

Latest news

More from news
Approximately 4 fully matching, plus 445 partially matching documents found.

Latest Intelligence

  • The case for a second Brexit referendum: “We need the informed consent of the people” The case for a second Brexit referendum: “We need the informed consent of the people”

    As many in the pharma industry know, the EEA allows Norway, Iceland and Liechtenstein to be part of the EMA and gain access to the new medicines at the same time. ... May and her cabinet looked to address concerns about medicines access in the Chequers

  • China: AstraZeneca’s new engine for growth and innovation China: AstraZeneca’s new engine for growth and innovation

    Despite our success in partnering with hospitals and government to improve access to new medicines, there remains a significant unmet medical need across China. ... Economic growth has enabled people to pay out-of-pocket, with regions and cities now

  • Stakeholder dialogue in Europe’s adaptive pathways pilot Stakeholder dialogue in Europe’s adaptive pathways pilot

    The European Medicines Agency (EMA) has worked for several years to speed patient access to new medicines. ... Evidence suggests that medicines using the resulting accelerated access initiatives experience variable reimbursement outcomes due to

  • The European Medicines Agency: PRIME’d for access? The European Medicines Agency: PRIME’d for access?

    The European Medicines Agency: PRIME’ d for access? Leela Barham examines the impact of the EMA's PRIME fast track system after two years. ... Regulators around the world have been working for decades to speed up access to the best of the new medicines

  • Trust me, I’m from pharma Trust me, I’m from pharma

    Through trusted collaboration, companies can improve the quality of healthcare services, unlock better access to care and greater access to the right medicines. ... Significantly, it’s totally independent of individual medicines and focused purely on

More from intelligence
Approximately 0 fully matching, plus 79 partially matching documents found.

Latest appointments

  • Pfizer’s Alan Maine moves to Edelman Pfizer’s Alan Maine moves to Edelman

    Maine, who previously served as head of policy and public affairs at Pfizer UK, was responsible for government affairs and market access policy development activity, covering both corporate and therapy area ... During his time at Pfizer, Maine also

  • Sobi names Holly May VP of sales and marketing, US Sobi names Holly May VP of sales and marketing, US

    May’s new role will see her lead the biopharma’s commercial team in bringing Sobi ’s medicines to the country. ... She will also collaborate with the operations and patient access team to ensure the medicines are accessible to as many appropriate

  • Inceptua Medicines Access appoints senior new-hires Inceptua Medicines Access appoints senior new-hires

    Inceptua Medicines Access appoints senior new-hires. The new speciality business unit appoints senior project manager and office manager. ... Multipharma’s new speciality business unit, Inceptua has appointed Ruth Rostron as its new senior project

  • Multipharma launches Inceptua Medicines Access Multipharma launches Inceptua Medicines Access

    Multipharma launches Inceptua Medicines Access. The group will be split into three sub-divisions. ... Multipharma has launched Inceptua Medicines Access, a speciality business unit that offers access to pre-approval and unlicensed medicines.

  • Sandoz UK promotes Tim de Gavre to country head Sandoz UK promotes Tim de Gavre to country head

    As a company, Sandoz has an exciting portfolio of medicines and future product pipeline. ... I look forward to working with the Sandoz team, and in partnership with the NHS to help patients access these important medicines.”.

More from appointments
Approximately 0 fully matching, plus 20 partially matching documents found.

Latest from PMHub

  • New opportunities in emerging markets

    This growth is set to continue. In parallel, we are seeing an increased focus among emerging market governments on public healthcare reform: expanding their populations’ access to medicines by establishing universal ... Greater purchasing power and

  • Unique forum will unite NHS and industry to drive innovation

    Unique forum will unite NHS and industry to drive innovation. HSJ Life Sciences Forum will explore key NHS challenges and debate future of medicines, by Sarah Eglington, Client Services Director at ... The event aims to help industry develop stronger

  • OPEN Access Consulting

    OPEN Access Consulting. OPEN Access Consulting is a specialist market access agency within the OPEN Health Group. ... High-cost medicines. Rare diseases. Long-term conditions. Generic and biosimilar introduction &defence.

  • Accession

    A passion to harness the power of market access to ensure patients gain access to life changing medicines and devices. ... The early industry pioneers of market access, are the creative force behind Accession.

  • Four Health Communications

    Patient Access. We see patient access to medicines as the critical challenge in today’ s pharma market environment. ... challenges. We work with our clients in a variety of ways to generate real-life insight into the issues being encountered by

More from PMHub
Approximately 0 fully matching, plus 5 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Creative Medical Research

Specialising in medical device market research and participant recruitment human factors research, our approach is people-centric. We thrive on making...

Latest intelligence

patients
Retaining reader value in plain language summaries of clinical studies
Balancing the risk of misinterpretation with the public’s ability to understand simplified plain-language summaries...
Can we talk about the ego-bias and chemicals influencing your target audience’s behaviour?
Over the Summer, the Page & Page team became fascinated by two books on this very subject. Two books from one author, Dean Burnett, an eminent neuroscientist, lecturing at Cardiff...
Paris
Making Europe a leader in bioscience: boosting trust and opening minds
A vision of Paris as Europe’s leading hub for life sciences innovation...

Infographics